DALLAS--(BUSINESS WIRE)--
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed in the United States District Court for the District of Massachusetts against Seres Therapeutics, Inc. (“Seres” or “Company”) (NASDAQ: MCRB) and several officers and directors for acts taken during the period of June 25, 2015 through July 29, 2016 (the “Class Period”).
Based upon the allegations in the class action, the firms are investigating additional legal claims against the officers and Board of Directors of Seres. If you are an affected Seres shareholder and want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC via email at [email protected], Patrick Powers at Powers Taylor LLP via email at [email protected], or call toll free at (877) 728-9607. There is no cost or fee to you.
In the complaint, the defendants are alleged to have violated certain provisions of the Securities Exchange Act of 1934. Specifically, the complaint alleges, among other things, that defendants failed to disclose material facts about its lead drug product candidate SER-109 and issued false and misleading statements touting its potential and efficacy. Seres announced on July 29, 2016 that the Phase 2 clinical trial of SER-109 did not meet its primary endpoint. When this news was revealed to the market, the Company’s stock dropped significantly.
The Briscoe Law Firm, PLLC is a full service business litigation, commercial transaction, and public advocacy firm with more than 20 years of experience in complex litigation and transactional matters.
Powers Taylor LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005997/en/
